A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient

NCT00002184 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Nelfinavir mesylate
DRUG: Levocarnitine
DRUG: Adefovir dipivoxil
DRUG: Saquinavir
DRUG: Lamivudine
DRUG: Stavudine
DRUG: Zidovudine

Sponsor

Gilead Sciences